How should we use geriatric assessment to guide treatment decisions for elderly patients with DLBCL?
How should we use geriatric assessment to guide treatment decisions for elderly patients with DLBCL?
How should we use geriatric assessment to guide treatment decisions for elderly patients with DLBCL?
Maplirpacept, a CD47-binding fusion protein, is currently being investigated in combination with other approved lymphoma therapies in early-phase trials.
Maplirpacept, a CD47-binding fusion protein, is currently being investigated in combination with other approved lymphoma therapies in early-phase trials.
Glenmark Pharma is discovering advance therapies for a new world. We are creating centers of excellence in dermatology, oncology and…
To help navigate the exciting content being presented at the EHA Congress 2025, the Lymphoma Hub Steering Committee have provided their recommendations for the top…
On June 6, 2025, the European Commission approved fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, for the treatment of adult patients with previously untreated…
On June 4, 2025, the FDA granted Breakthrough Therapy Designation for iopofosine I 131 for the treatment of relapsed/refractory Waldenstrom’s macroglobulinemia.
On June 3, 2025, the European Commission approved brentuximab vedotin, in combination with ECADD chemotherapy, for adult patients with newly diagnosed Stage IIb with risk…
New data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.
The Lymphoma Hub was pleased to speak to Grzegorz S. Nowakowski, Mayo Clinic, Rochester, US, who discussed the real-world experience of tafasitamab and lenalidomide for…
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease